Strategic Acquisition Opportunity With Sun Pharma's recent acquisition of Checkpoint Therapeutics for 355 million dollars, there is a potential opportunity to provide post-merger integration solutions, advanced oncology drug development support, and specialized commercialization services to enhance the company's growth trajectory.

Emerging Oncology Focus Checkpoint Therapeutics' emphasis on accelerating the development and commercialization of oncology drugs presents opportunities to offer targeted clinical trial services, biologics manufacturing solutions, and personalized treatment technologies tailored to their innovative pipeline.

Funding and Growth Potential Having secured a 12 million dollar financing round and generating revenue between 10 and 25 million dollars, the company shows signs of rapid growth, making it suitable for partnership in areas like sales infrastructure expansion, regulatory compliance support, and market access strategies.

Technology Enablement Needs Utilizing advanced tech stacks such as Microsoft 365, New Relic, and Google Analytics indicates a focus on digital infrastructure, creating opportunities to offer cloud services, data analytics, cybersecurity, and optimization solutions to support R&D and operational efficiency.

Legal and Compliance Engagement The recent class-action lawsuits suggest a need for specialized legal consulting, compliance management, and risk mitigation services, presenting a potential avenue for legal firms or compliance solution providers to support the company's legal and governance processes.